Working… Menu

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00734682
Recruitment Status : Completed
First Posted : August 14, 2008
Last Update Posted : January 7, 2015
Information provided by (Responsible Party):
Michael Prados, University of California, San Francisco

Brief Summary:
This is a Phase I study of Nanoliposomal CPT-11 in patients with Recurrent high-grade gliomas. Patients must have a histologically proven intracranial malignant glioma, which includes glioblastoma multiforme (GBM), gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified). Patients who are wild type or heterozygous for the UGT1A1*28 gene will received Nanoliposomal CPT-11. The total anticipated accrual will be approximately 36 patients (depending upon the actual MTD). The investigators hypothesis is that this new formulation of CPT-11 will increase survival over that seen in historical controls who have recurrent gliomas because CPT-11 will be encapsulated in a liposome nanoparticle, which has been seen to reduce toxicities from the drug.

Condition or disease Intervention/treatment Phase
Glioblastoma Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Drug: Nanoliposomal CPT-11 Phase 1

Detailed Description:
Patients with recurrent malignant glioma will receive Nanoliposomal CPT-11 at the time of relapse. The dose will be adjusted according to a phase-1 dose escalation scheme. Patients will receive drug intravenously every 3 weeks until tumor progression or excessive toxicity. Weekly follow up will occur to assess toxicities during the DLT phase of the trial. Patients will have different dose escalation if UGT1A1 is 6/6 versus UGT1A1 is 6/7. Patients with UGT 1A1 of 7/7 will not be eligible. All patients must have UGT 1A1 status know as an eligibility requirement. Patients will be followed for both toxicity and progression, and progression will be evaluated by MR imaging every 6 weeks. Pharmacokinetics will be obtained in the first treatment cycle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
Study Start Date : August 2008
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Experimental: Nanoliposomal CPT-11
All patients are treated with nanoliposomal CPT-11
Drug: Nanoliposomal CPT-11
Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
Other Names:
  • NL CPT-11
  • liposomal irinotecan

Primary Outcome Measures :
  1. To assess the safety and pharmacokinetics of NL CPT-11 in patients with recurrent malignant glioma stratified based on UGT1A1 genotyping. [ Time Frame: 1-2 years ]

Secondary Outcome Measures :
  1. To determine the maximum tolerated dose of NL CPT-11 in these patient populations. [ Time Frame: 1-2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically proven intracranial malignant glioma are eligible . -All patients must sign an informed consent

    • Patients must be > 18 years old, and with a life expectancy > 8 weeks.
    • Patients must have a Karnofsky performance status of > 60.
  • Patients must have recovered from the toxic effects of prior therapy
  • Patients must have adequate bone marrow function (WBC > 3,000/µl, ANC > 1,500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 10 gm/dl), adequate liver function (SGOT and bilirubin < 2 times ULN), and adequate renal function (creatinine < 1.5 mg/dL and/or creatinine clearance > 60 cc/min) Patients must have shown radiographic evidence for tumor progression by MRI or CT scan. A scan should be performed within 14 days prior to registration and on a steroid dose that has been stable for at least 5 days. -Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:

    • They have recovered from the effects of surgery.
    • Residual disease following resection of recurrent malignant glioma is not mandated for eligibility into the study.
  • Patients must have failed prior radiation therapy
  • Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease
  • Women of childbearing potential must have a negative ß-HCG pregnancy test documented within 14 days prior to registration.
  • Patients may have had treatment for any number of prior relapses.

Exclusion Criteria:

  • Patients must not have any significant medical illnesses that in the investigator opinion cannot be adequately controlled
  • Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years are ineligible.
  • Patients must not have active infection or serious intercurrent medical illness.
  • Patients must not be pregnant/breast feeding and must agree to practice adequate contraception.
  • Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.
  • Patients must not have received prior therapy with irinotecan.
  • Patients with 7/7 (homozygous) UGT1A1*28 genotyping will be excluded from the study.
  • Patients receiving enzyme-inducing anticonvulsants or other enzyme inducing drugs are excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00734682

Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
Layout table for investigator information
Principal Investigator: Michael Prados, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: Michael Prados, Professor, University of California, San Francisco Identifier: NCT00734682    
Obsolete Identifiers: NCT00745082
Other Study ID Numbers: 08103
First Posted: August 14, 2008    Key Record Dates
Last Update Posted: January 7, 2015
Last Verified: December 2014
Keywords provided by Michael Prados, University of California, San Francisco:
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Mixed Oligoastrocytoma
Malignant Astrocytoma NOS
Nanoliposomal CPT-11
liposomal irinotecan
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents